Utilization of New Methods for Antibody Drug Conjugates: Research Progress and Future Prospects

Authors

  • Xiaorui Guo

DOI:

https://doi.org/10.62051/11qfks06

Keywords:

ADC; click chemistry; scale-up synthesis; flow reactors.

Abstract

Cancer has become an obvious health problem and scientists focus on this to help the problem. Antibody drug conjugates (ADC) has been considered as an efficient way to treat cancer. There are already many ways to produce ADC, but traditional methods need long and complicated biochemical process. Synthesis methods with high efficiency need to be found. This article aimed to describe three new methods for ADC synthesis, and it came out that all these three methods have high quality and can be used as a common technology to produce ADC. Also, the safety of ADC and several examples of clinical use for ADC were introduced. It provides a reference for ADC synthesis in a relatively simple chemical process for future research. However, there are still some chemical problems that have not been solved, such as azide derivatives are not easy to obtain and they are not stable enough. Future research can focus on the properties of azide derivatives direction.

Downloads

Download data is not yet available.

References

Fu, Z., Li, S., Han, S., Shi, C. and Zhang, Y. Antibody drug conjugate: the ‘biological missile’ for targeted cancer therapy. Signal Transduction and Targeted Therapy, 2022, 7 (1).

Jin, Y., Schladetsch, M.A., Huang, X., Balunas, M.J. and Wiemer, A.J. Stepping forward in antibody-drug conjugate development. Pharmacology & Therapeutics, 2021, pp.107917.

Baah, S., Laws, M. and Rahman, K.M. Antibody–Drug Conjugates—A Tutorial Review. Molecules, 2021, 26 (10), p.2943.

Vatansever E C, Kang J, Tuley A, et al. An optimal “Click” formulation strategy for antibody-drug conjugate synthesis. Bioorganic & medicinal chemistry, 2020, 28 (24): 115808.

Watanabe T, Fujii T, Stofleth J T, et al. Scale-Up Synthesis of Site-Specific Antibody–Drug Conjugates Using AJICAP Second-Generation Technology. Organic Process Research & Development, 2023.

Brian A., Yutaka M. Antibody−Drug Conjugate Synthesis Using Continuous Flow Microreactor Technology Yuichi Nakahara. Process Res. Dev. 2022, 26, 2766 − 2770.

Hafeez, U., Parakh, S., Gan, H.K. and Scott, A.M. Antibody–Drug Conjugates for Cancer Therapy. Molecules, 2020, 25 (20), p.4764.

Shastry, M., Jacob, S., Rugo, H.S. and Hamilton, E. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. The Breast. 2022.

Bardia, A., Messersmith, W.A., Kio, E.A., et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Annals of Oncology, 2021, 32 (6), pp.746 – 756.

Li, B.T., Smit, E.F., Goto, Y., et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2022, 386 (3), pp.241 – 251.

Downloads

Published

24-03-2024

How to Cite

Guo, X. (2024). Utilization of New Methods for Antibody Drug Conjugates: Research Progress and Future Prospects. Transactions on Materials, Biotechnology and Life Sciences, 3, 658-662. https://doi.org/10.62051/11qfks06